BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 26519231)

  • 1. Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.
    Martin P; Oliver S; Gillen M; Marbury T; Millson D
    Clin Ther; 2015 Dec; 37(12):2823-36. PubMed ID: 26519231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies.
    Baluom M; Grossbard EB; Mant T; Lau DT
    Br J Clin Pharmacol; 2013 Jul; 76(1):78-88. PubMed ID: 23190017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies.
    Martin P; Gillen M; Millson D; Oliver S; Brealey C; Elsby R; Baluom M; Lau D; Mant T
    Clin Ther; 2015 Dec; 37(12):2811-22. PubMed ID: 26514315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.
    Martin P; Gillen M; Millson D; Oliver S; Brealey C; Grossbard EB; Baluom M; Lau D; Sweeny D; Mant T; Craven K
    Drugs R D; 2016 Mar; 16(1):81-92. PubMed ID: 26739683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA).
    Maringwa J; Kågedal M; Hamrén UW; Martin P; Cox E; Hamrén B
    J Clin Pharmacol; 2015 Mar; 55(3):328-35. PubMed ID: 25280085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the disposition of fostamatinib in Japanese subjects including pharmacokinetic assessment in dry blood spots: results from two phase I clinical studies.
    Martin P; Cheung SY; Yen M; Han D; Gillen M
    Eur J Clin Pharmacol; 2016 Jan; 72(1):61-71. PubMed ID: 26490353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The status of fostamatinib in the treatment of rheumatoid arthritis.
    Morales-Torres J
    Expert Rev Clin Immunol; 2012 Sep; 8(7):609-15. PubMed ID: 23078058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
    Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
    Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
    Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation.
    Sweeny DJ; Li W; Clough J; Bhamidipati S; Singh R; Park G; Baluom M; Grossbard E; Lau DT
    Drug Metab Dispos; 2010 Jul; 38(7):1166-76. PubMed ID: 20371637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinib.
    Boström E; Öhrn F; Hanze E; Sandström M; Martin P; Wählby-Hamrén U
    J Clin Pharmacol; 2014 Dec; 54(12):1337-46. PubMed ID: 24895144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects.
    Dymond AW; Martin P; So K; Huang Y; Severin P; Holmes V; Mariani G; Marbury T
    J Clin Pharmacol; 2017 May; 57(5):592-605. PubMed ID: 28019010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
    Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.
    Scott DL
    Drugs; 2011 Jun; 71(9):1121-32. PubMed ID: 21711059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
    Horsmans Y; Zhou J; Liudmila M; Golor G; Shibolet O; Quinlan M; Emotte C; Boss H; Castro H; Sellami D; Preston RA
    Clin Pharmacokinet; 2018 Mar; 57(3):345-354. PubMed ID: 28577129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
    Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
    Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
    Scott IC; Scott DL
    Drugs; 2014 Mar; 74(4):415-22. PubMed ID: 24610702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib.
    Nguyen L; Holland J; Ramies D; Mamelok R; Benrimoh N; Ciric S; Marbury T; Preston RA; Heuman DM; Gavis E; Lacy S
    J Clin Pharmacol; 2016 Sep; 56(9):1130-40. PubMed ID: 26865195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis.
    Baluom M; Samara E; Grossbard EB; Lau DT
    J Clin Pharmacol; 2011 Sep; 51(9):1310-8. PubMed ID: 21209239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.